ArticleInternational journal of cardiology. Heart & vasculature2026
Prognostic significance of serum pyroptosis-related factors in acute coronary syndrome: a propensity score analysis.
Article in International journal of cardiology. Heart & vasculature, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aims: This study investigated the clinical significance of pyroptosis-related factors, including NLRP1, NLRP3, and HMGB1, in patients with acute coronary syndrome (ACS), and analyzed their prognostic value. Methods: A total of 231 ACS patients (unstable angina, STEMI, and NSTEMI) treated between March 2020 and August 2022 were included. Serum levels of NLRP1, NLRP3, HMGB1, IL-6, IL-1β, and CRP were measured using ELISA, and demographic and clinical data were recorded. Patients were followed for one year, and those who experienced major adverse cardiovascular events (MACE) were classified into the poor prognosis group. Propensity score matching (PSM) was applied to minimize baseline differences between groups. Results: After PSM, 61 matched pairs (n = 122) were included for analysis, and baseline characteristics between groups were balanced. Activated partial thromboplastin time (APTT) and prothrombin time (PT) were significantly shorter in the poor prognosis group. In contrast, serum levels of NLRP1, NLRP3, and HMGB1 were significantly higher in the poor prognosis group and correlated positively with inflammatory markers. Among the factors studied, NLRP1 demonstrated the highest prognostic accuracy (AUC = 0.799, cutoff = 31.04 pg/ml, sensitivity = 70.49 %, specificity = 70.49 %). Multivariate analysis identified lower APTT and PT, as well as higher NLRP1, and NLRP3 as independent risk factors for poor prognosis. Conclusions: Elevated serum levels of NLRP1, NLRP3, and HMGB1 are associated with poor prognosis in patients with ACS. These factors may serve as potential biomarkers for risk stratification and therapeutic targets in clinical practice.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.